​

Novavax (NVAX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NVAX Stock Forecast

Novavax (NVAX) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $20.33, with a high of $25.00 and a low of $14.00. This represents a 130.76% increase from the last price of $8.81.

- $5 $10 $15 $20 $25 High: $25 Avg: $20.33 Low: $14 Last Closed Price: $8.81

NVAX Stock Rating

Novavax stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (50.00%), 8 Hold (44.44%), 1 Sell (5.56%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 1 8 9 Strong Sell Sell Hold Buy Strong Buy

NVAX Forecast vs Benchmarks

TypeNameUpside
StockNovavax130.76%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-15
Avg Price Target-$22.00$22.20
Last Closing Price$8.81$8.81$8.81
Upside/Downside-149.72%151.99%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25122-16
Dec, 24122-16
Nov, 24225-110
Oct, 242251111
Sep, 242251111
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 18, 2024Mayank MamtaniB.Riley Financial$22.00$7.58190.24%149.72%
Oct 16, 2024Roger SongJefferies$25.00$10.15146.31%183.77%
Oct 16, 2024Alec StranahanBank of America Securities$14.00$10.4533.97%58.91%
Jul 19, 2024Roger SongJefferies$31.00$14.36115.88%251.87%
May 10, 2024Vernon BernardinoH.C. Wainwright$19.00$9.9491.15%115.66%
Feb 14, 2022Charles DuncanCantor Fitzgerald$174.00$80.11117.20%1875.03%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2024H.C. WainwrightBuyBuyhold
Oct 16, 2024JefferiesBuyBuyhold
Oct 16, 2024Bank of America SecuritiesNeutralNeutralhold
Oct 10, 2024B. RileyBuyBuyhold
Jul 19, 2024JefferiesBuyBuyhold
May 23, 2024B. RileyBuyBuyhold
May 13, 2024Cowen & Co.HoldHoldhold
May 10, 2024Bank of America SecuritiesUnderperformNeutralupgrade
May 10, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2023Raymond JamesMarket PerformOutperformupgrade

Financial Forecast

EPS Forecast

$-25 $-19 $-13 $-7 $-1 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.43$-23.44$-8.42$-5.41-----
Avg Forecast$-5.81$-13.70$-7.16$-4.22$-1.28$0.13$0.96$1.57$1.10
High Forecast$-9.02$-21.28$-12.31$-5.14$-1.56$-1.91$0.13$1.41$0.27
Low Forecast$-3.92$-9.24$-3.77$-3.38$-0.77$2.73$1.48$1.73$2.37
Surprise %27.88%71.09%17.60%28.20%-----

Revenue Forecast

$0 $700M $1B $2B $3B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$475.60M$1.15B$1.60B$983.71M-----
Avg Forecast$446.35M$1.26B$2.01B$1.01B$724.07M$557.33M$652.01M$530.45M$594.90M
High Forecast$334.67M$947.15M$1.28B$978.85M$302.16M$237.41M$272.09M$221.36M$248.25M
Low Forecast$636.32M$1.80B$3.12B$1.05B$1.37B$1.07B$1.23B$1.00B$1.12B
Surprise %6.55%-9.26%-20.36%-3.03%-----

Net Income Forecast

$-7B $-5B $-4B $-2B $-900M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-427.50M$-1.74B$-657.94M$-545.06M-----
Avg Forecast$-585.13M$-4.02B$-5.11B$-545.06M$-117.20M$81.66M$80.95M$158.21M$110.84M
High Forecast$-908.87M$-4.83B$-6.22B$-663.49M$-156.92M$-192.77M$13.06M$142.23M$26.88M
Low Forecast$-394.80M$-3.22B$-4.00B$-426.64M$-77.48M$275.38M$148.85M$174.18M$238.60M
Surprise %-26.94%-56.67%-87.13%------

NVAX Forecast FAQ

Is Novavax stock a buy?

Novavax stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 8 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Novavax is a favorable investment for most analysts.

What is Novavax's price target?

Novavax's price target, set by 18 Wall Street analysts, averages $20.33 over the next 12 months. The price target range spans from $14 at the low end to $25 at the high end, suggesting a potential 130.76% change from the previous close price of $8.81.

How does Novavax stock forecast compare to the average forecast of its sector, industry, and investment themes?

Novavax stock forecast shows a 130.76% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Novavax over the past three months?

  • January 2025: 16.67% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 16.67% Strong Sell.
  • December 2024: 16.67% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 16.67% Strong Sell.
  • November 2024: 20.00% Strong Buy, 20.00% Buy, 50.00% Hold, 0% Sell, 10.00% Strong Sell.

What is Novavax’s EPS forecast?

Novavax's average annual EPS forecast for its fiscal year ending in December is -1.28 for 2024, a -76.34% decrease from the reported $-5.41 in 2023. The prediction for 2025 is $0.13, $0.96 for 2026, $1.57 for 2027, and $1.1 for 2028.

What is Novavax’s revenue forecast?

Novavax's average annual revenue forecast for its fiscal year ending in December is $724.07M for 2024, a -26.39% decrease from the reported $983.7M in 2023. The forecast for 2025 is $557.33M, $652.01M for 2026, $530.45M for 2027, and $594.9M for 2028.

What is Novavax’s net income forecast?

For its fiscal year ending in December, Novavax's average annual net income forecast is $-117M for 2024, reflecting a -78.50% decrease from the reported $-545M in 2023. The projection for 2025 is $81.66M, $80.95M for 2026, $158.21M for 2027, and $110.84M for 2028.